Create a table for carbapenem resistance organism, each organisms at different tissue site. And 1st line and second line at that tissue
Reading File
Finding Sources
Finding Sources
Searching the Web
carbapenem resistant organisms treatment by site infection 2024 guidelines first line second line
Reading File
Finding Sources
Reading Web Page
carbapenem resistant organisms treatment by infection site first line second line
Reading File
Finding Sources
Reading Web Page
IDSA 2024 carbapenem resistant CRE CRAB DTR Pseudomonas treatment by site UTI bloodstream pneumonia
Reading File
Reading File
Finding Sources
I now have sufficient information from Harrison's, Washington Manual, ICMR guidance, and IDSA 2024 to build a comprehensive, well-structured table. Let me compile this.
Carbapenem-Resistant Organisms (CROs): Treatment by Infection Site
Based on IDSA 2024 AMR Guidance, Harrison's Principles of Internal Medicine 22e, and ICMR guidance.
Organisms Covered
| Abbreviation | Full Name |
|---|---|
| CRE | Carbapenem-Resistant Enterobacterales (K. pneumoniae, E. coli, Enterobacter spp.) |
| CRAB | Carbapenem-Resistant Acinetobacter baumannii |
| DTR-PA | Pseudomonas aeruginosa with Difficult-to-Treat Resistance (carbapenem-resistant) |
CRE - Carbapenem-Resistant Enterobacterales
| Infection Site | 1st Line Treatment | 2nd Line / Alternative |
|---|---|---|
| UTI (uncomplicated cystitis) | Nitrofurantoin or TMP-SMX or fosfomycin (oral) - based on susceptibility | Ciprofloxacin or levofloxacin (if susceptible) |
| UTI (complicated / pyelonephritis) | Ceftazidime-avibactam OR imipenem-cilastatin-relebactam OR meropenem-vaborbactam | Cefiderocol; colistin (for UTI only, not polymyxin B) |
| Bloodstream / Bacteremia | Ceftazidime-avibactam OR meropenem-vaborbactam OR imipenem-cilastatin-relebactam | Cefiderocol; polymyxin B + tigecycline + high-dose carbapenem (if no novel agents available) |
| Pneumonia (HAP/VAP) | Ceftazidime-avibactam OR meropenem-vaborbactam OR imipenem-cilastatin-relebactam | Cefiderocol; polymyxin B + high-dose carbapenem + tigecycline |
| Intra-abdominal infection | Ceftazidime-avibactam + metronidazole | Meropenem-vaborbactam + metronidazole; cefiderocol |
| CNS / Meningitis | Ceftazidime-avibactam (note: limited CNS data; MBL strains - use ceftazidime-avibactam + aztreonam) | Polymyxin B intrathecal + IV; consult ID specialist |
| Skin & Soft Tissue / Wound | Ceftazidime-avibactam OR meropenem-vaborbactam | Cefiderocol; tigecycline + polymyxin B (if source control done) |
Note for MBL-producing CRE (NDM, VIM, IMP carbapenemase): Ceftazidime-avibactam is NOT active alone - use ceftazidime-avibactam + aztreonam combination. - Harrison's 22e, p. 1340; ICMR CRO Guidance
CRAB - Carbapenem-Resistant Acinetobacter baumannii
| Infection Site | 1st Line Treatment | 2nd Line / Alternative |
|---|---|---|
| UTI (uncomplicated) | Colistin (polymyxin E) - preferred for UTI; high-dose sulbactam | Minocycline or tigecycline (if susceptible) |
| Bloodstream / Bacteremia | Sulbactam-durlobactam + meropenem (IDSA 2024 preferred) | High-dose ampicillin-sulbactam + polymyxin B (preferred over colistin for BSI) + tigecycline or minocycline |
| Pneumonia (HAP/VAP) | Sulbactam-durlobactam + meropenem | High-dose ampicillin-sulbactam + colistin or polymyxin B + tigecycline; cefiderocol (caution: higher mortality in some trials) |
| Meningitis / CNS | High-dose sulbactam (IV) + colistin intrathecal/intraventricular + meropenem | Polymyxin B intrathecal + IV; colistin IV; consult ID specialist (poor CNS penetration of most agents) |
| Skin & Soft Tissue / Wound | High-dose ampicillin-sulbactam OR sulbactam-durlobactam | Minocycline (IV/PO); tigecycline |
| Intra-abdominal | Sulbactam-durlobactam + meropenem | High-dose ampicillin-sulbactam + polymyxin B + tigecycline |
Key point: No regimen proven superior for CRAB. Sulbactam-durlobactam showed 28-day mortality of 19% vs. 32% with colistin (RCT). Polymyxin B preferred over colistin for bloodstream; colistin preferred for UTI. Nebulized antibiotics for respiratory CRAB are NOT recommended. - Harrison's 22e, p. 1340
DTR-PA - Pseudomonas aeruginosa with Difficult-to-Treat Resistance (Carbapenem-Resistant)
| Infection Site | 1st Line Treatment | 2nd Line / Alternative |
|---|---|---|
| UTI (uncomplicated) | Ceftolozane-tazobactam OR ceftazidime-avibactam (if susceptible) | Aminoglycoside (if susceptible, for uncomplicated); fosfomycin IV |
| UTI (complicated / pyelonephritis) | Ceftolozane-tazobactam OR ceftazidime-avibactam | Cefiderocol; imipenem-cilastatin-relebactam |
| Bloodstream / Bacteremia | Ceftolozane-tazobactam OR ceftazidime-avibactam | Cefiderocol; imipenem-cilastatin-relebactam; colistin + beta-lactam |
| Pneumonia (HAP/VAP) | Ceftolozane-tazobactam OR ceftazidime-avibactam (high dose) | Cefiderocol; imipenem-cilastatin-relebactam; colistin + beta-lactam + aminoglycoside |
| Intra-abdominal | Ceftolozane-tazobactam + metronidazole OR ceftazidime-avibactam + metronidazole | Cefiderocol + metronidazole |
| CNS / Meningitis | Ceftolozane-tazobactam (if susceptible) - limited data | Colistin intrathecal/IV; consult ID specialist |
| Skin & Soft Tissue / Wound | Ceftolozane-tazobactam OR ceftazidime-avibactam | Cefiderocol; imipenem-cilastatin-relebactam |
Quick-Reference Drug Summary
| Drug | Active Against | Notes |
|---|---|---|
| Ceftazidime-avibactam | CRE (KPC, OXA-48), DTR-PA | NOT active against MBL (NDM, VIM) alone - combine with aztreonam |
| Meropenem-vaborbactam | CRE (KPC) | Less active against OXA-48, MBL; inactive against DTR-PA |
| Imipenem-cilastatin-relebactam | CRE (KPC), DTR-PA | Not for MBL-CRE; not for CRAB |
| Ceftolozane-tazobactam | DTR-PA primarily | No CRE activity; no CRAB activity |
| Cefiderocol | CRE, CRAB, DTR-PA, Stenotrophomonas | Broad GN coverage; use in combination; higher mortality noted in CRAB trials (CREDIBLE-CR) |
| Sulbactam-durlobactam | CRAB specifically | IDSA 2024 preferred for CRAB; pair with meropenem |
| Polymyxin B | CRE (salvage), CRAB | Preferred for bloodstream; nephrotoxic; does NOT reach lung/CSF well |
| Colistin (Polymyxin E) | CRE (salvage), CRAB | Preferred for UTI; NOT for bloodstream (use polymyxin B there) |
| Tigecycline / Minocycline | CRAB, CRE (combination) | Low serum levels - not for bloodstream monotherapy; adjunct only |
Sources: Harrison's Principles of Internal Medicine 22e (2025), p. 1340 | IDSA 2024 Guidance on Treatment of AMR Gram-Negative Infections | ICMR Guidance on Diagnosis and Management of CROs | Washington Manual of Medical Therapeutics | Harriet Lane Handbook 23e
This is a shared conversation. Sign in to Orris to start your own chat.